Muntané J, Montero J L, Marchal T, Perez-Seoane C, Lozano J M, Fraga E, Pintado C O, Miño G
Servicio Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain.
J Gastroenterol Hepatol. 1998 Feb;13(2):197-207. doi: 10.1111/j.1440-1746.1998.tb00638.x.
Prostaglandin E1 has hepatoprotective properties in several clinical and experimental models of liver dysfunction. Hepatotoxicity induced by D-galactosamine (D-GalN) is a suitable animal model of human acute hepatic failure. The aim of the study was to investigate if prostaglandin E1 (PGE1) protection against hepatic D-GalN-induced apoptosis was related to tumour necrosis factor-alpha (TNF-alpha) content in serum. This cytokine is associated with in vitro apoptosis and general inflammatory disorders. In this study, PGE1 was administered 30 min before D-GalN to rats. In other experiments, several doses of TNF-alpha were administered 15min after PGE1 to D-Ga1N-treated rats. Several parameters related to apoptosis and necrosis were measured by flow cytometry, gel electrophoresis, biochemical analysis, and optical and electron microscopy. Tumour necrosis factor-alpha was quantified by competitive enzyme-linked immunosorbent assay (ELISA). PGE1 by itself did not modify the cell cycle of hepatocytes and liver toxicity, but increased TNF-alpha in serum in comparison with the control group. D-Galactosamine increased the percentage of hepatocytes in apoptosis and in the S phase of the cell cycle, and decreased those in G0/G1. Such an increase of hepatocytes in apoptosis was correlated with a higher number of apoptotic bodies and DNA fragmentation in liver than control samples. Also, D-GalN increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and TNF-alpha in serum compared with the control group. Pre-administration of PGE1 to D-GalN-treated rats reduced all the parameters of apoptosis and necrosis in liver, and increased additionallyTNF-alpha content in serum. In those experiments where low doses of TNF-alpha were administered to PGE1 and D-GalN-treated rats an inverse relationship appeared between TNF-alpha and ALT content in serum. In conclusion, the protective effects of PGE1 on D-GalN-induced apoptosis may be linked to its capacity to modulate cell division and/or its immunomodulatory activity. In this sense, our experimental results suggest that TNF-alpha could be involved in protection or exacerbation of liver damage in relation to the pathophysiological status of the liver.
前列腺素E1在多种肝功能障碍的临床和实验模型中具有肝脏保护特性。D-半乳糖胺(D-GalN)诱导的肝毒性是人类急性肝衰竭的一种合适动物模型。本研究的目的是调查前列腺素E1(PGE1)对肝脏D-GalN诱导的细胞凋亡的保护作用是否与血清中肿瘤坏死因子-α(TNF-α)含量有关。这种细胞因子与体外细胞凋亡和全身性炎症紊乱有关。在本研究中,在给大鼠注射D-GalN前30分钟给予PGE1。在其他实验中,在给经D-Ga1N处理的大鼠注射PGE1后15分钟给予几剂TNF-α。通过流式细胞术、凝胶电泳、生化分析以及光学和电子显微镜测量了与细胞凋亡和坏死相关的几个参数。通过竞争性酶联免疫吸附测定(ELISA)对肿瘤坏死因子-α进行定量。PGE1本身并未改变肝细胞的细胞周期和肝脏毒性,但与对照组相比,血清中的TNF-α增加。D-半乳糖胺增加了处于细胞凋亡状态和细胞周期S期的肝细胞百分比,并减少了处于G0/G1期的肝细胞百分比。与对照样品相比,肝细胞凋亡的这种增加与肝脏中凋亡小体数量增加和DNA片段化相关。此外,与对照组相比,D-GalN还增加了血清中的丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶和TNF-α。预先给经D-GalN处理的大鼠注射PGE1可降低肝脏中细胞凋亡和坏死的所有参数,并额外增加血清中的TNF-α含量。在那些给经PGE1和D-GalN处理的大鼠注射低剂量TNF-α的实验中,血清中TNF-α与ALT含量之间呈现出负相关关系。总之,PGE1对D-GalN诱导的细胞凋亡的保护作用可能与其调节细胞分裂的能力和/或其免疫调节活性有关。从这个意义上讲,我们的实验结果表明,TNF-α可能与肝脏病理生理状态相关的肝损伤的保护或加重有关。